Researchers have discovered that mimicking cold exposure or fasting can trigger an immune response in the body that slows ...
ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million -- KPL-38 ...
The biotechnology sector offers investors a high-risk, high-reward opportunity as companies race to bring breakthrough ...
A researcher is planning on investigating potential treatments aimed at the root causes of type 1 diabetes. At the (MUSC), ...
ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ...
ImmunityBio, Inc. (NASDAQ: IBRX) today announced an update on the status of enrollment in its randomized registrational trial ...
Nonetheless, the authors concluded, “Liver biopsy is considered the gold standard for diagnosing MASH and MASLD. While ...
Boehringer Ingelheim today announced the start of a Phase IIa clinical trial evaluating BI 765423 , a novel monoclonal antibody targeting interleukin-11 (IL-11), in patients with idiopathic pulmonary ...
Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...
3don MSN
Novel immunotherapy demonstrates early potential to overcome resistance to immune checkpoint therapy
According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback